Shi Ji Biotechnology Plans TPEx Listing and Medical-AI Expansion
TechNews reported that Shi Ji Biotechnology plans to register on the Taipei Exchange’s emerging-stock market on November 23 at a reference price of NT$80 per share. The company is working with APMIC and using NTUH Hsinchu Branch’s smart-healthcare center as a demonstration site for a Taiwan medical sovereign large language model. General Manager Fang Hongwen said the Traditional Chinese model is intended to support medical-record generation, nursing assistance, medical knowledge retrieval, smart wards and administration. He also described two business engines: plasma devices, dedicated consumables and clinical services; and medical-AI model subscriptions and application services.
The planned emerging-stock registration and hospital demonstration site provide concrete details about the company’s listing and medical-AI initiatives. The report did not provide independent benchmarks for the model or independent clinical measurements for the company’s plasma-device claims.


施吉生技今日召開興櫃前業績發表會,預計 11 月 23 日以每股參考價 80 元登錄興櫃,總經理方弘文表示,目前透過電漿設備、專用耗材與臨床服務,以及醫療 AI 模型訂閱與應用服務雙引擎,目標將合作版圖拓展至 30 家指標醫學中心,並規劃推進美國 FDA 取證及相關臨床。
方弘文表示,施吉生技電漿醫療事業以急慢性傷口治療設備為核心,採用醫療級低溫電漿技術,具備非接觸式治療及穩定可控的電漿輸出特性,可降低傷口細菌負載、去除生物膜、促進癒合等臨床療效。
#Shi Ji Biotechnology#APMIC#NTUH Hsinchu Branch#Taiwan Sovereign Medical Large Language Model#Medical-grade Low-temperature Plasma Technology